Skip to content
drillr.ai

LXEO

Lexeo Therapeutics, Inc. Common Stock

NASDAQ · USHealthcareBiotechnology
$4.55-2.99%

Price as of Jul 20, 2026

LXEO news

Lexeo Therapeutics, Inc. Common Stock news

A server-rendered, paginated timeline of the latest available company news.

  1. Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

    Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2026 with topline data expected in 2H 2027 NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (https://www.globenewswire.com/Tracker?data=grCcmqeAqMqmhQ9hP5ERbrG6eN4eevOTwZ08umR-lYhfwmsM-5qD4qNetasAzfbKp2_mpdpSM7KUQosz7jgzmv01aRYpMfjCfySvZjQTfnI=) (Nasdaq: LXEO), a clinical stage

    Globe Newswire ·

  2. Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

    NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its cardiac gene therapy programs and optimized AAV manufacturing approach will be presented at the 29 (https://www.globenewswire.com/Tracker?data=be8__C2buIjVGLhSkCtTc6JhQmeZzBVCUxwQa_IZ6XXqTNn7LrDKkYrYHGnDQsyXOf9IDPXk8K0BvswCEdr3bQ==)(th) (https://www.globene

    Globe Newswire ·

  3. Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness Program (CDRP) meeting for LX2006 in Q1 2026; aligned with FDA on flexible approach to process validation such as reduced PPQ manufacturing batches Late-breaking oral presentations at the American College of Cardiology (ACC) Annual Meeting demonstrate continued, encouraging efficacy and safety data acros

    Globe Newswire ·